Anti-IL-31Ra Antibody

Recombinant anti-IL-31Ra (interleukin 31 receptor subunit alpha) antibody recognizing human IL-31Ra protein. This anti-IL-31Ra antibody is a purified, humanized recombinant monoclonal antibody. This antibody has been tested in a binding assay. It is similar to Nemolizumab. IL-31 (interleukin 31) is a four-helix bundle proinflammatory cytokine preferentially produced by T helper type 2 (TH2) cells. IL-31 regulates cell differentiation, cell proliferation, and immune responses, serving as a neuroimmune link between TH2 cells and sensory neurons in generating a T cell-mediated inflammatory itch. The IL-31 receptor complex, composed of IL-31RA and OSMR (human oncostatin M receptor beta), is expressed by various epithelial and immune cells as well as dorsal root ganglia sensory neurons. IL-31 interacts with the IL-31 receptor complex, activating Janus kinases JAK1 and JAK2. This activation leads to the phosphorylation of signal transducer and activator of transcription (STAT) molecules, mainly STAT3, which upregulate the genes responsible for the IL-31 induced itch sensation. Often referred to as the itchy cytokine, increased expression of IL-31 or its receptor IL-31RA is correlated with alopecia, skin lesions, airway hypersensitivity, and particularly pruritic disorders such as atopic dermatitis. IL-31 and other TH2 related cytokines (including IL-4, IL-13 and TSLP (thymic stromal lymphopoietin) play an important role in the pathogenesis of a variety of inflammatory and allergic diseases and have become popular for therapeutic development. The IL-31RA targeting antibody Nemolizumab has been FDA-approved for the treatment of atopic dermatitis.